Monday, 27 Jan 2020

You are here

Depression Increases Risk of Systemic Lupus Erythematosus

Twenty-year data from the Nurses’ Health Study (NHS) suggests that depression is associated with a 2-fold increased frequency of systemic lupus erythematosus (SLE) - the question is why?

An analysis of 194,483 women in the NHS sought to identify incident SLE cases meeting ACR criteria (with 4 or more criteria) bases on self-report and confirmed by medical record review. Depression was based on a clinician’s diagnosis of depression, antidepressant use, or a score of less than 60 on the 5-item Mental Health Inventory (MHI-5).

Among from 194 483 women (28-93 years of age) in the NHS, there were 145 incident cases of SLE.

Women with depression had over a 2 fold increased risk of SLE (HR, 2.67; 95% CI, 1.91-3.75; P < .001) compared to those with no depression.  This risk was largely unchanged after adjustment for body mass index, cigarette smoking, and oral contraception and postmenopausal hormone use.

The Lupus risk was evident regardless of the measure used to establish depression - clinician’s diagnosis, antidepressant use or MHI-5 scores.

Why would depression may be associated with increased risk of SLE remains unclear. Depression may occur as part of a neuropsychiatric manifestation of lupus.  Some research indicates immunologic abnormalities in those with depression and patients with depression have a slightly higher rate of autoantibodies. 

Limitations of the NHS and this kind of research are several. First, nurses who are enrolled may not be truly representative of the population, as nurses tend to be more more homogeneous as a group and tend to be generally white, thinner, more health-conscious, highly educated.  Moreover this comes with the limitations of an observational study. Hence these findings are best at generating hypotheses that can be further studied with intervention and other forms of randomized trials.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.

Treatment of Statin-induced anti-HMGCR myopathy

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of triple steroid/IVIG/SSI was very efficacious in induction.

Best of 2019 - 2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.